Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine
Overview
- Phase
- Phase 4
- Intervention
- Ivabradine
- Conditions
- Heart Failure
- Sponsor
- University of Campania "Luigi Vanvitelli"
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Echocardiofic changes of diastolic left ventricular function
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Heart failure with normal ejection fraction is often under diagnosed and certainly under treated in hemodialyzed patients. Because of the benefit of reducing heart rate, ivabradine, a pure heart-rate lowering agent without effects on blood pressure, is of potential therapeutic utility.
Investigators
Eligibility Criteria
Inclusion Criteria
- •hemodialyzed patients
- •signs and symptoms of heart failure with normal ejection fraction
- •sinus rhythm
Exclusion Criteria
- •atrial fibrillation/atrial flutter
- •valvular heart disease
- •unstable angina
- •hospitalization for heart failure prior 3 months
Arms & Interventions
IVABRADINE, HEART FAILURE WITH NORMAL EF
Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
Intervention: Ivabradine
Outcomes
Primary Outcomes
Echocardiofic changes of diastolic left ventricular function
Time Frame: baseline, 1, 3, 6, 9, 12 months
Measures of diastolic left ventricular function (E and A velocity and deceleration time of mitral inflow and Doppler-Tissue-Imaging E velocity and their ratio) were assessed at baseline and at each scheduled time.
Secondary Outcomes
- changes in 6-minutes walking test(baseline, 1,3,6,9,12 months)
- changes in NYHA class(baseline, 1,3,6,9,12 months)